The global ear, nose, and throat (ENT) treatment market is expected to value US$ 20.2 Bn in 2020 and is anticipated to register CAGR of 5.2% from 2021 to 2028.
An increase in number of patients suffering from ENT problems across the globe, rapid advancements in the development of advanced treatment, and rise in awareness among consumers related to the availability of minimally invasive surgical procedures are major factors expected to drive the growth of global ear, nose, and throat (ENT) treatment market. According to the World Health Organization (WHO), nearly 2.5 billion people across the globe, or one in every four, will have some degree of hearing loss by 2050. Centers for Disease Control and Prevention states that: out of every 1,000 children about 2 to 3 are born with hearing loss in both ears in the US. In addition, approximately 15% of American adults (37.5 million) aged 18 and over report some trouble hearing. Tonsillitis, sinus infections, ear infections are some of the major ENT problems witnessed by doctors every year. According to Getting It Right First Time (GIRFT), UK statistics, 330,000 patients were admitted to hospitals with ENT disorders. Also, tonsillectomy accounts for 17% of the total elective workload, with 2.8 million outpatient visits. Consumer spending on healthcare is increasing and with the availability of advanced healthcare infrastructure their approach towards the availability of better care to patients is increasing.
The rise in the geriatric population in developing countries and the increase in problems associated with hearing among them is expected to increase demand for minimally invasive devices and treatment procedures. In addition, increasing penetration of robotics in treatment procedures in order to deliver high precision in diagnosis of diseases are some factors expected to boost the ear, nose, and throat (ENT) treatment market growth. The Government is spending high on the development of present infrastructure with the focus to deliver enhanced care to the patients and aid enterprises in R&D activities. For instance, NHS spends approximately US$ 37.5 million on ENT products and technologies among which cochlear implants, bone-anchored hearing aids (BAHAs), processors, and accessories account for 80% of these expenditures. The government is providing better reimbursement policies to the consumers in order to facilitate healthcare treatment. For example:
Major players are investing high in the development of the enhanced products, their approach towards the introduction of new products and increase the customer base is expected to augment the growth of target market. In 2019, Cochlear Limited, a global service provider of ear products, launched its new product "Osia 2 System". The product has received clearance from the US Food and Drug Administration (USFDA). The product launch helped the company enhance its customer base. In addition, strategic business development activities by major players in order to enhance the business and increase the revenue are factors expected to support the growth of ear, nose, and throat (ENT) treatment market.
Factors such as stringent government regulations related to product approval and lack of skilled professionals are expected to hamper the growth of global ear, nose, and throat (ENT) treatment market. The government is imposing stringent regulations on drug and devices approvals as there are rise in cases related to product recalls. In 2021, Hill Dermaceuticals Inc., a global ear drug manufacturer faced a recall of 15 lots of DermOtic Oil Ear Drops from the Canadian government due to the presence of broken glass in the glass pipette of the ear dropper.
|Market||ENT Treatment Market|
|Analysis Period||2017 - 2028|
|Forecast Data||2021 - 2028|
|Segments Covered||By Organ Type, By Treatment Type, By End Use and By Geography|
|Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||
Medtronic plc, Cochlear Limited, Sanofi, Pfizer Inc., Merck & Co., Inc., Johnson and Johnson Olympus Corporation, Smith & Nephew plc, Siemens Healthcare GmbH, Starkey Laboratories, Inc, and Demant A/S
||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis|
10 hrs of free customization and expert consultation
With the rising number of patients, there is a shortage of skilled professionals across the globe. According to a report released by the Project HOPE: The People-to-People Health Foundation, Inc., the projection estimated a 40,000 physician shortage by 2020. According to a recent study, there will be a shortage of 52,000 primary care physicians by 2025, with the problem affecting adults more than children. However, increasing government spending on the development of present infrastructure, increasing R&D activities for enhanced product development, and initiatives to increase healthcare workers will improve opportunities in the market. In addition, an increasing partnership between regional and international players is expected to support the revenue transaction of the target market.
Ear, Nose, and Throat (ENT) Treatment Market Region Analysis, 2020
North America accounted for revenue of US$ 7.8 Bn in 2020 and is expected to continue its dominance over the market due to rising number of patients suffering from various ear and nose infections. The availability of favorable reimbursement policies by the government and the presence of advanced healthcare infrastructure are expected to impact the growth of target market. Consumer’s preference for home care is increasing; with the availability of developed infrastructure adoption of advanced devices is easy to provide patients better care. The presence of large number of players operating in the country and the introduction of new solutions is expected to boost the ear, nose, and throat (ENT) treatment market growth. The government is providing favorable policies for product approvals. In 2019, the Food and Drug Administration (FDA), approved "Dupixent (dupilumab)" to treat adults with nasal polyps and chronic rhinosinusitis. This is the first treatment approved by the FDA for inadequately controlled chronic rhinosinusitis with nasal polyps.
Ear, Nose, and Throat (ENT) Treatment Market Segment Analysis, 2020
The global ear, nose, and throat (ENT) treatment market is segmented into organ types, treatment types, and end-user. The organ type, the segment is bifurcated into ears, nose, and throat. Among organ types, the ear segment accounted for revenue of US$ 9.4Bn in the target segment. This is attributed to raise in number of ear infection cases across the globe. Increasing R&D activities by major players and introduction of innovative devices is expected to support the segment growth. The end user segment is divided into hospitals, clinics, home care settings, and others. Among end-users, the hospital's segment accounted for the highest revenue share in the target market, due to increasing government spending on the development of hospital infrastructure and focus to deliver enhanced care to the patients.
Players operating in the global ear, nose, and throat (ENT) treatment market are Medtronic plc, Cochlear Limited, Sanofi, Pfizer Inc., Merck & Co., Inc., Johnson and Johnson Olympus Corporation, Smith & Nephew plc, Siemens Healthcare GmbH, Starkey Laboratories, Inc, and Demant A/S.
Market by Organ Type:
Market by Treatment Type:
Market by End Use:
Market By Geography
Ear, nose, and throat (ENT) treatment market is expected to reach a market value of around US$ 30.2 Bn by 2028.
The ear, nose, and throat (ENT) treatment market is expected to grow at a CAGR of around 5.5% from 2021 to 2028.
Based on organ type, ears segment is the leading segment in the overall market.
Research and development for new treatment option is one of the prominent factors that drive the demand for ear, nose, and throat (ENT) treatment market.
Medtronic plc, Cochlear, Olympus Corporation, Smith & Nephew plc, Siemens Healthineers, Starkey Hearing Technologies, Demant A/S, and others.
North America is anticipated to grab the highest market share in the regional market
Asia Pacific is expected to be the fastest growing market in the forthcoming years